Exelixis, Inc.
EXEL
Classement en actions
#1414
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer,... Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
Prix de l'action
$62.61
Capitalisation boursière
$15.74B
Changement (1 jour)
0.61%
Changement (1 an)
59.52%
Pays
US
Échange Exelixis, Inc. (EXEL)
Catégorie
Healthcare
EPS pour Exelixis, Inc. (EXEL)
EPS au July 2026 TTM : $3.29
Selon les derniers rapports financiers et le cours de l'action de Exelixis, Inc., l’EPS actuel de la société (TTM) est de $3.29. À la fin de 2025, la société avait un EPS de $1.80 une augmentation par rapport à celui de 2023, qui était de $0.65.
Historique de l'EPS de Exelixis, Inc. de 2000 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $3.29 | 82.78% |
| 2025 | $1.80 | 176.92% |
| 2023 | $0.65 | 14.04% |
| 2022 | $0.57 | -21.92% |
| 2021 | $0.73 | 102.78% |
| 2020 | $0.36 | -66.04% |
| 2019 | $1.06 | -54.31% |
| 2018 | $2.32 | 346.15% |
| 2017 | $0.52 | -285.71% |
| 2016 | $-0.28 | -65.43% |
| 2015 | $-0.81 | -41.30% |
| 2014 | $-1.38 | 3.76% |
| 2013 | $-1.33 | 44.57% |
| 2012 | $-0.92 | -253.33% |
| 2011 | $0.60 | -170.59% |
| 2010 | $-0.85 | -32.54% |
| 2009 | $-1.26 | -18.18% |
| 2008 | $-1.54 | 77.01% |
| 2007 | $-0.87 | -25.64% |
| 2006 | $-1.17 | 9.35% |
| 2005 | $-1.07 | -43.39% |
| 2004 | $-1.89 | 30.34% |
| 2003 | $-1.45 | -4.61% |
| 2002 | $-1.52 | -0.65% |
| 2001 | $-1.53 | -37.04% |
| 2000 | $-2.43 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $17.32 | 426.44% |
US
|
|
| $-7.98 | -342.55% |
US
|
|
| $-5.29 | -260.79% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 743.16% |
NL
|
